Cwm LLC Sells 1,757 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Cwm LLC decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,569 shares of the company’s stock after selling 1,757 shares during the period. Cwm LLC’s holdings in Krystal Biotech were worth $3,792,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in KRYS. China Universal Asset Management Co. Ltd. boosted its position in shares of Krystal Biotech by 111.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after purchasing an additional 379 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $219,000. Prime Capital Investment Advisors LLC bought a new stake in shares of Krystal Biotech during the 4th quarter valued at about $310,000. Graham Capital Management L.P. bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $330,000. Finally, Confluence Wealth Services Inc. boosted its position in shares of Krystal Biotech by 20.7% during the 3rd quarter. Confluence Wealth Services Inc. now owns 2,920 shares of the company’s stock valued at $339,000 after purchasing an additional 500 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,087 shares of company stock valued at $6,210,591. 14.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of research reports. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a research note on Monday. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Citigroup upped their price target on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Guggenheim upped their price target on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and a consensus target price of $171.00.

Krystal Biotech Stock Down 1.8 %

Shares of Krystal Biotech stock opened at $159.05 on Thursday. The company has a market cap of $4.53 billion, a PE ratio of 1,988.37 and a beta of 0.85. Krystal Biotech, Inc. has a 52 week low of $82.09 and a 52 week high of $189.97. The business has a 50 day moving average price of $162.61 and a 200-day moving average price of $131.15.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million during the quarter, compared to analysts’ expectations of $27.43 million. During the same period last year, the company earned ($1.25) earnings per share. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 1.89 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).